About Volastra Therapeutics
Volastra Therapeutics is a private company based in New York, New York. It has reported $105,274,995 raised in three offerings on Form D since March 2023. Its chief executive is David Southwell.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 8, 2025 | Sep 23, 2025 | $30,099,998fully sold | 11 | $2.7M | EquityRule 506(b) | Form D ↗ |
| May 17, 2024 | May 30, 2024 | $15,000,000fully sold | 2 | $7.5M | EquityRule 506(b) | Form D ↗ |
| Mar 3, 2023 | Mar 13, 2023 | $60,174,997fully sold | 13 | $4.6M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $105,274,995 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Volastra Therapeutics's Form D filed Sep 23, 2025.
Earlier filings also listed Stefan Vitorovic (director, last listed May 2024), Scott Drutman (executive officer, last listed May 2024), Rez Halze (director, last listed May 2024), Rachel Schwartz (executive officer, last listed May 2024), Eileen McGuire (director, last listed May 2024), Charles Hugh-Jones (chief executive officer and director, last listed May 2024), Michael Su (executive officer, last listed Mar 2023) and Diane Tager (executive officer, last listed Mar 2023).